OSE Immunotherapeutics SA

As of December 31, 2024, OSE Immunotherapeutics SA carries a market capitalization of 159.62M, placing it among publicly traded companies globally. Its enterprise value stands at 146.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OSE Immunotherapeutics SA's next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2024, OSE Immunotherapeutics SA has 21.90M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, OSE Immunotherapeutics SA maintains a current ratio of 3.46, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, OSE Immunotherapeutics SA's stock has declined approximately 67.67% over the past 52 weeks. The 50-day moving average sits at 2.66, while the 200-day moving average is 3.72.

As of December 31, 2024, OSE Immunotherapeutics SA holds 59.12M in cash and equivalents against 46.13M in total debt, resulting in a net debt position of 26.11M. Total book value stands at 63.81M, with working capital of 49.71M providing operational flexibility.